QUÉBEC CITY, Oct. 10, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that George R. Merriam, MD, Director of the Clinical Study Unit at the VA Puget Sound Health Care System, and Professor of Medicine at the University of Washington, Seattle and Tacoma, WA, will give an oral presentation on AEZS-130, Aeterna Zentaris' ghrelin agonist, at the 6 th International Congress of the Growth Hormone Research (GRS) and Insulin-like Growth Factor (IGF) Society, which will be held in Munich, Germany, October 17-20, 2012.
The presentation titled, " Use of an orally-active ghrelin mimetic, macimorelin (AEZS-130), as a safe, simple test for Adult Growth Hormone Deficiency (AGHD): Effect of BMI on optimal cut off ", will take place on Thursday, October 18, 2012, from 4:30 to 4:45 pm (local time), in the Black Box Room of the Gasteig Conference Center.
AEZS-130, a ghrelin agonist, is a novel orally-active small molecule that stimulates the secretion of growth hormone. The Company has completed a Phase 3 trial for use as an oral diagnostic test for AGHD. AEZS-130 has been granted orphan drug designation by the FDA for use in this indication. Aeterna Zentaris owns the worldwide rights to AEZS-130.About Aeterna Zentaris Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. For more information please visit www.aezsinc.com. SOURCE AETERNA ZENTARIS INC.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV